From Our Partners
Saturday, June 25, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

Systems-Based Neurotechnology for Emerging Therapies – SUBNETS

by Global Biodefense Staff
November 11, 2013

The Defense Advanced Research Projects Agency (DARPA) seeks to develop a new understanding of complex, systems-based disorders of the brain and deliver a platform technology for precise therapy in humans living with neuropsychiatric and neurologic disease, including veterans and active duty soldiers suffering from mental health issues.

Methods developed through the “Systems-Based Neurotechnology for Emerging Therapies (SUBNETS)” program will use neural recording and stimulation to close the loop on therapeutic treatment in individuals who receive minimal benefits from currently available treatments.

The program is anticipated to lead to improved knowledge of multiple neural subnetworks of the brain that are involved in disease and illness. The effort combines novel device development, complex modeling of behaving human neural systems, clinical neurology, and animal research in order to advance the understanding and translation of safe, effective neurotechnological therapies.

 “The neuropsychiatry problem is significant to the DoD and requires significant, cooperative investments across technological areas where DARPA has both particular interest and past expertise and development,” states the announcement.

For purposes of this program, DARPA is specifically interested in evaluating the underlying systems, which contribute to the following conditions as described by the Diagnostic and Statistical Manual of Mental Disorders (DSM-V): Post-Traumatic Stress Disorder (PTSD); Major Depression; Borderline Personality Disorder; and General Anxiety Disorder.

DARPA is additionally interested in evaluating the representation in the central nervous system for TBI, Fibromyalgia/Chronic Pain, and Substance Abuse.

Further details are available under Solicitation Number: DARPA-BAA-14-09.

From Our Partners
Tags: Animal ModelsBAADARPA

Related Posts

NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
Supplemental Funding for Research at NIAID Regional Biocontainment Laboratories
Biosecurity

Supplemental Funding for Research at NIAID Regional Biocontainment Laboratories

May 5, 2022
U.S. Fish and Wildlife Service Opens Grant Program to Shore Up Avian Flu Biosecurity
Biosecurity

U.S. Fish and Wildlife Service Opens Grant Program to Shore Up Avian Flu Biosecurity

April 13, 2022
NIAID Funding Available for Biocontainment Facility Improvements
Biosecurity

NIAID Funding Available for Biocontainment Facility Improvements

April 8, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC